Teva Pharmaceutical Industries (TEVA) Equity Average (2016 - 2025)
Teva Pharmaceutical Industries (TEVA) has disclosed Equity Average for 17 consecutive years, with $7.6 billion as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Equity Average rose 28.99% year-over-year to $7.6 billion, compared with a TTM value of $7.6 billion through Dec 2025, up 28.99%, and an annual FY2025 reading of $6.6 billion, down 1.6% over the prior year.
- Equity Average was $7.6 billion for Q4 2025 at Teva Pharmaceutical Industries, up from $7.0 billion in the prior quarter.
- Across five years, Equity Average topped out at $11.4 billion in Q3 2021 and bottomed at $5.8 billion in Q1 2025.
- Average Equity Average over 5 years is $8.5 billion, with a median of $7.9 billion recorded in 2023.
- Peak annual rise in Equity Average hit 28.99% in 2025, while the deepest fall reached 25.7% in 2025.
- Year by year, Equity Average stood at $11.3 billion in 2021, then dropped by 20.23% to $9.1 billion in 2022, then decreased by 13.62% to $7.8 billion in 2023, then dropped by 24.82% to $5.9 billion in 2024, then grew by 28.99% to $7.6 billion in 2025.
- Business Quant data shows Equity Average for TEVA at $7.6 billion in Q4 2025, $7.0 billion in Q3 2025, and $6.6 billion in Q2 2025.